Non-Fucosylated Anti-Human CD19 (3649-aFuc) Therapeutic Antibody, an ADCC-Enhanced Biobetter (CAT#: BioBet-1674ZP) Datasheet

Target
CD19
Isotype
Humanized IgG
Description
The ADCC-enhanced antibody is a glycosylation-modified therapeutic biobetter antibody. Creative Biolabs' Afuco™ technology platform allows for the control of fucosylation level. By reducing or removing the fucose of the Fc region, we obtained the ADCC-enhanced antibody, which showed increased binding affinity to the FcyR receptor on immune effector cells in an in vitro ADCC assay compared to its patent fucosylated antibody.

More specifically, the afucosylated therapeutic biobetter antibody was generated by recombinant DNA technology. It has been produced in CHO cells that are deficient for fucosylation and purified by affinity chromatography with protein G. The absence of the fucose residue from the N-glycans of IgG-Fc results in dramatic enhancement of antibody-dependent cellular cytotoxicity (ADCC).
Indication
Refractory B cell precursor Acute lymphoblastic leukemia
Relapsed B cell precursor Acute lymphoblastic leukemia
Classification
Therapeutic antibody; biobetter
Status
Preclinical

Cooperation Seeking

Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced rituximab. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
CD19
Full Name
CD19 molecule
Background
Lymphocytes proliferate and differentiate in response to various concentrations of different antigens. The ability of the B cell to respond in a specific, yet sensitive manner to the various antigens is achieved with the use of low-affinity antigen receptors. This gene encodes a cell surface molecule which assembles with the antigen receptor of B lymphocytes in order to decrease the threshold for antigen receptor-dependent stimulation.
Alternative Names
CD19; CD19 molecule; B4; CVID3; B-lymphocyte antigen CD19; differentiation antigen CD19; T-cell surface antigen Leu-12; B-lymphocyte surface antigen B4
Gene ID
Function
As the cell surface receptor of fibroblast growth factor, protein tyrosine kinase plays a vital role in regulating cell proliferation, differentiation, migration and apoptosis and regulating embryonic development. Normal embryonic pattern, trophoblast function, limb bud development, lung morphogenesis, osteogenesis and skin development are required. It plays a vital role in the regulation of osteoblast differentiation, proliferation and apoptosis, and is necessary for normal bone development. Promotes cell proliferation in keratinocytes and immature osteoblasts, but promotes apoptosis in differentiated osteoblasts. Phosphorylate PLCG1, FRS2 and PAK4. Ligand binding leads to the activation of several signal cascades. The activation of PLCG1 leads to the production of cell signaling molecules diacylglycerol and inositol 1,4,5-triphosphate. Phosphorylation of FRS2 triggers the recruitment of GRB2, GAB1, PIK3R1 and SOS1, and mediates the activation of RAS, MAPK1/ERK2, MAPK3/ERK1 and MAP kinase signaling pathways and AKT1 signaling pathway. FGFR2 signal transduction is down-regulated due to ubiquitination, internalization and degradation. Mutations that cause constitutive kinases to activate or impair normal FGFR2 maturation, internalization and degradation can lead to abnormal signaling. Over-expressed FGFR2 promotes the activation of STAT1.
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG
Antibody Clone
3649-aFuc
Host
Humanized
Species Reactivity
Human
Description
The binding affinity of the 3649-3M Fc variant antibody to Fc [gamma] RIIIA and the 3649-aFuc non-fucosylated antibody is much higher than the binding affinity of the fucosylated 3649 antibody.
Indication
Refractory B cell precursor Acute lymphoblastic leukemia
Relapsed B cell precursor Acute lymphoblastic leukemia
Synonyms
3649

All products and services are for Research Use Only. Do Not use in humans.

ONLINE INQUIRY

Creative Biolabs has established a team of customer support scientists ready to discuss ADCC/CDC optimization strategies, antibody production, bioinformatics analysis and other molecular biology/biotechnology issues.

  • *
  • *
  • *
USA

UK